Insilico Medicine
Insilico Medicine / insilico.com
AI-powered drug discovery company that uses generative AI and deep learning to design novel drug candidates, predict target biology, and accelerate the path from target identification to clinical trials.
Pricing
Free
Free plan
No
Category
Developer Tools
Platforms
2
Free plan
No
API access
Yes
Open source
No
Platforms
2
Advertisement
What is Insilico Medicine?
Insilico Medicine is one of the leading AI drug discovery companies, using generative AI and deep learning to design novel drug candidates from scratch rather than only screening existing compound libraries. Its Chemistry42 platform generates novel molecule structures optimised for specific target proteins and desired drug properties including potency, selectivity, and ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles.
The most notable validation of Insilico's approach is INS018_055, a novel anti-fibrosis drug candidate discovered and designed entirely by AI with no prior pharmacological knowledge used in the design process. This compound entered Phase 2 clinical trials in 2023, making Insilico the first company to advance a fully AI-designed drug candidate to this stage.
Target ID uses AI to identify novel biological targets for specific diseases by analysing genomic, proteomic, and clinical data. PandaOmics, the target identification platform, has suggested novel targets for diseases including Parkinson's, ALS, and kidney fibrosis.
Insilico partners with pharmaceutical companies including Pfizer, Sanofi, and Pfizer to apply its AI platform to their drug discovery programmes. The company is listed on NASDAQ (ILAB), providing financial transparency.
How Insilico Medicine works
Insilico Medicine runs as ml platform software built around data workflows. Users typically start with a prompt, upload, or connected data source, and the underlying model handles the heavy lifting before returning a result you can refine or export. It's available on web and api, with API access for teams that want to embed it into their own products.
Watch Insilico Medicine in action
Recent YouTube videos cached from the backend so this page stays fast and fresh.
What makes it worth shortlisting
The capabilities that matter most for teams evaluating Insilico Medicine.
Chemistry42
Generative AI platform that designs novel drug candidate molecules from scratch, optimised for specific target proteins and desired ADMET and potency properties.
AI target identification
PandaOmics analyses genomic, proteomic, and clinical data to identify novel biological targets for diseases including Parkinson's, ALS, and kidney fibrosis.
First AI clinical trial
INS018_055, a novel anti-fibrosis compound discovered and designed entirely by AI, entered Phase 2 clinical trials — the most advanced AI-designed drug in human trials.
Best use cases
Who should use it
Pros
- INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
- Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
- First company to advance a fully AI-designed drug candidate to clinical trials
- NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment
Cons
- Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
- Clinical success probability remains uncertain — most drug candidates fail in clinical trials
- Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform
Advertisement
Is it worth the price?
Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.
Model
Enterprise
Starting price
Free
Free trial
No
Tools like Insilico Medicine
Recursion Pharmaceuticals is a direct competitor in AI drug discovery with biological data focus. Schrödinger is a computational chemistry platform used in drug discovery. AbSci provides AI for antibody drug design. Exscientia is a strong European competitor.
Insilico Medicine vs AbSci AI
A side-by-side look at the closest alternative in this category.
Insilico Medicine
Insilico Medicine
AbSci AI
AbSci
Enterprise and institutional licensing for pharmaceutical partners. No public access. Public company listed on NASDAQ.
Pharmaceutical partnership model. No public pricing. Publicly traded company (ABSI). Research collaborations.
Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.
Research data handling agreements. GDPR compliant. Enterprise pharmaceutical partnership data handling agreements.
Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.
Biological research data and drug candidate designs handled under pharmaceutical partnership data handling agreements and applicable research ethics frameworks.
- INS018_055 in Phase 2 clinical trials is the most advanced AI-designed drug in human trials
- Chemistry42 generative AI designs novel molecules rather than only screening existing libraries
- First company to advance a fully AI-designed drug candidate to clinical trials
- NASDAQ listing (ILAB) provides financial transparency for pharma partnership assessment
- Published zero-shot antibody design research in peer-reviewed journals validates the generative AI approach
- Publicly traded company provides financial transparency and stability versus private biotech competitors
- Generative design approach creates novel molecules rather than optimising existing ones — different innovation mode
- Pharmaceutical partnership model provides revenue without requiring AbSci to advance drugs independently through clinical trials
- Drug discovery is inherently long-cycle — AI acceleration is still measured in years, not weeks
- Clinical success probability remains uncertain — most drug candidates fail in clinical trials
- Enterprise partnership model means capabilities are not broadly accessible as a self-serve platform
- Very early commercial stage — generative AI drug discovery has not yet produced approved drugs
- Pharmaceutical partnership revenue is lumpy and dependent on partner decisions and clinical outcomes
- Competing with well-funded competitors including Recursion, Insilico Medicine, and Isomorphic Labs
Technical & deployment info
Key facts about model providers, platforms, and team support.
Model Provider
Insilico
Models
Chemistry42, PandaOmics
Platforms
Web, API
Deployment
SaaS, Enterprise partnership
Integrations
Major pharmaceutical ERP and research systems, API
Team Collaboration
No
Launch Year
2014
Security & privacy
Compliance signals and data-handling notes as reported by the vendor.
Enterprise research data handling agreements. GDPR compliant. Research use data protected under partnership terms.
Drug discovery research data processed under enterprise partnership data handling agreements. Review applicable regulatory requirements for clinical programme data.
What users are saying
Verified reviews from signed-in users, stored in the backend and averaged into this tool's rating.
Sign in to rate Insilico Medicine and leave a review.
No other reviews yet — be the first to share how this tool performs in practice.
Common questions about Insilico Medicine
Editorial Verdict
Should you use Insilico Medicine?
Insilico Medicine is the most validated AI drug discovery company with Phase 2 clinical evidence, best positioned as a pharmaceutical research partner for companies wanting to apply AI to novel target-based drug design.
Last verified July 24, 2026.